1. Home
  2. EVO vs BWAY Comparison

EVO vs BWAY Comparison

Compare EVO & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Evotec SE

EVO

Evotec SE

HOLD

Current Price

$1.62

Market Cap

568.6M

Sector

Health Care

ML Signal

HOLD

Logo BrainsWay Ltd.

BWAY

BrainsWay Ltd.

HOLD

Current Price

$13.42

Market Cap

547.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EVO
BWAY
Founded
1993
2003
Country
Germany
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
568.6M
547.7M
IPO Year
2007
2011

Fundamental Metrics

Financial Performance
Metric
EVO
BWAY
Price
$1.62
$13.42
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$7.00
★ $13.25
AVG Volume (30 Days)
★ 143.7K
75.3K
Earning Date
04-08-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$1.37
$309.69
Revenue Next Year
$10.05
$26.21
P/E Ratio
★ N/A
$81.98
Revenue Growth
N/A
N/A
52 Week Low
$1.50
$11.77
52 Week High
$4.27
$26.63

Technical Indicators

Market Signals
Indicator
EVO
BWAY
Relative Strength Index (RSI) 38.78 36.69
Support Level $1.50 $11.90
Resistance Level $1.97 $14.83
Average True Range (ATR) 0.06 0.54
MACD 0.00 0.00
Stochastic Oscillator 42.59 22.30

Price Performance

Historical Comparison
EVO
BWAY

About EVO Evotec SE

Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.

About BWAY BrainsWay Ltd.

BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.

Share on Social Networks: